Should You Buy Pediatrix Medical Group, Inc. Stock in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Pediatrix Medical Group, Inc. (MD) carries a solid Quality of Company rating of 6.4/10. Trading at $26.14, our multi-model framework evaluates whether the company's financial profile offers a favorable risk-reward setup.
The short answer: 9 of 12 CirclFi valuation models project upside for Pediatrix Medical Group, Inc. (MD) at $26.14 — the model consensus leans bullish, with a Quality Score of 6.4/10 and Value-Trap risk of 21/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.
Investment Thesis
The Bull Case
Target: $131.26 (+402.2% upside)
- According to the CirclFi Deep Alpha Valuation Engine, the stock shows multi-model upside with an average implied return of +57.8% across 8 bullish models from the current price of $26.14.
- According to the CirclFi Deep Alpha Valuation Engine, the Markov DDM model targets a fair value of $131.26 (+402.2%), anchoring the bull case with a methodology that provides a differentiated analytical lens.
The Bear Case
Target: $21.18 (-19.0%)
- According to the CirclFi Deep Alpha Valuation Engine, the EROIC Spread model sees the stock as overvalued with a fair value of $21.18 (-19.0%), suggesting that the market price embeds overly optimistic growth assumptions.
- According to the CirclFi Deep Alpha Valuation Engine, model disagreement is high with a +421.1% spread between the most bullish and bearish models, signaling elevated analytical uncertainty.
Peer Benchmarking
The Bottom Line
The balance of evidence tilts cautiously positive for Pediatrix Medical Group, Inc. at $26.14. 8 of 12 models support upside to $41.25, backed by a 6.4/10 quality foundation. This is a "lean into, not load up on" setup in our framework.
These are quantitative model outputs, not investment recommendations. Pediatrix Medical Group, Inc.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →
Frequently Asked Questions
Should I buy MD stock right now?
Based on CirclFi's multi-model analysis, 9 of 12 models see upside for MD at $26.14. The majority of models suggest the stock trades below fair value, but investors should weigh this against the Quality Score of 6.4/10 and individual risk tolerance. This is not a buy recommendation — see our full disclaimer.
What are the biggest risks of investing in Pediatrix Medical Group, Inc.?
Key risks include: wide model disagreement (520% spread), signaling high uncertainty; general market and sector-specific risks affecting Services-Hospitals companies. Always diversify and consult a financial advisor.
How does MD compare to its competitors?
Among Services-Hospitals peers, MD holds a Quality Score of 6.4/10. Comparable companies include EHC (QOC 8.2). The relative ranking helps investors identify whether MD offers better fundamental quality than alternatives in the same sector.
Is MD a good long-term investment?
Long-term investment potential depends on fundamental quality and sustainable competitive advantages. MD's Quality Score of 6.4/10 suggests moderate fundamentals — not a clear long-term hold without further research into growth catalysts. Check our full data page for all 13 model estimates.
What price should I buy MD at?
CirclFi does not provide target buy prices or price alerts. However, our 12 active models produce fair value estimates ranging from $21.18 to $131.26. At $26.14, the stock trades within the range of model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.
Want the complete picture?
See all 13 model estimates, confidence scores, and the full valuation table for MD.
Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →
Buy with Gumroad